Last reviewed · How we verify
Oxaliplatin, irinotecan, 5-FU & leucovorin
Oxaliplatin, irinotecan, 5-FU & leucovorin is a Small molecule drug developed by Per Pfeiffer. It is currently in Phase 2 development.
At a glance
| Generic name | Oxaliplatin, irinotecan, 5-FU & leucovorin |
|---|---|
| Sponsor | Per Pfeiffer |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Diarrhoea
- Nausea
- Fatigue
- Neutropenia
- Stomatitis
- Hypertension
- Vomiting
- Constipation
- Asthenia
- DIARRHOEA
- Epistaxis
- Decreased appetite
Key clinical trials
- Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44) (PHASE2)
- Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma (PHASE2)
- Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer (PHASE2)
- A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer (PHASE3)
- Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (PHASE2, PHASE3)
- Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial (PHASE3)
- A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer (PHASE3)
- Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxaliplatin, irinotecan, 5-FU & leucovorin CI brief — competitive landscape report
- Oxaliplatin, irinotecan, 5-FU & leucovorin updates RSS · CI watch RSS
- Per Pfeiffer portfolio CI
Frequently asked questions about Oxaliplatin, irinotecan, 5-FU & leucovorin
What is Oxaliplatin, irinotecan, 5-FU & leucovorin?
Oxaliplatin, irinotecan, 5-FU & leucovorin is a Small molecule drug developed by Per Pfeiffer.
Who makes Oxaliplatin, irinotecan, 5-FU & leucovorin?
Oxaliplatin, irinotecan, 5-FU & leucovorin is developed by Per Pfeiffer (see full Per Pfeiffer pipeline at /company/per-pfeiffer).
What development phase is Oxaliplatin, irinotecan, 5-FU & leucovorin in?
Oxaliplatin, irinotecan, 5-FU & leucovorin is in Phase 2.
What are the side effects of Oxaliplatin, irinotecan, 5-FU & leucovorin?
Common side effects of Oxaliplatin, irinotecan, 5-FU & leucovorin include Diarrhoea, Nausea, Fatigue, Neutropenia, Stomatitis, Hypertension.